APOE in subjective cognitive decline: a systematic review and meta-analysis.

J NeurolAug 30, 2026 (epub)
Clinical ResearchNeurologyPsychiatryOpen access

Paolo Alonge, Ludovico Baiamonte, Giulia Gerardi et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the prevalence of the APOE ε4 allele in individuals with subjective cognitive decline (SCD). Among 49 studies, the pooled prevalence of APOE ε4 carriers was found to be 28.3% in SCD, indicating its potential role as an intermediate stage in the Alzheimer's disease continuum.

Key findings

  • The pooled prevalence of APOE ε4 allele carriers was 28.3% in SCD individuals.
  • The odds of being an APOE ε4 carrier were significantly higher in SCD compared to cognitively normal individuals (OR = 1.28).
  • In MCI, the prevalence of APOE ε4 carriers was 41.0%, higher than in SCD.
  • Age and education were identified as contributors to heterogeneity in SCD cohorts.

Why it matters

Understanding the prevalence of the APOE ε4 allele in SCD can help clinicians identify individuals at higher risk for progression to mild cognitive impairment or Alzheimer's disease, facilitating early intervention strategies.

Source

PubMed · PMID 42669099Free full text on PubMed Central

Published in J Neurol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.